153 related articles for article (PubMed ID: 20061019)
1. Complete molecular remission in refractory acute myeloid leukemia with MLL/AF9 treated with gemtuzumab ozogamicin.
Asano H; Yamamoto G; Hosoi M; Takahashi T; Hangaishi A; Kurokawa M
Leuk Res; 2010 Jul; 34(7):e152-3. PubMed ID: 20061019
[No Abstract] [Full Text] [Related]
2. Low dose gemtuzumab ozogamicin for relapsed acute myeloid leukaemia in elderly.
Piccaluga PP; Martinelli G; Rondoni M; Malagola M; Ronconi S; Visani G; Baccarani M
Haematologica; 2003 Dec; 88(12):ECR37. PubMed ID: 14688010
[No Abstract] [Full Text] [Related]
3. Treatment of relapsed acute myeloid leukemia with MLL/AF6 fusion after allogeneic hematopoietic stem cell transplantation with gemtuzumab ozogamicin with a long interval followed by donor lymphocyte infusion.
Tamai H; Shioi Y; Yamaguchi H; Okabe M; Wakita S; Mizuki T; Nakayama K; Inokuchi K; Tajika K; Dan K
Leukemia; 2008 Jun; 22(6):1273-4. PubMed ID: 17989711
[No Abstract] [Full Text] [Related]
4. The prognostic value of MLL-AF9 detection in patients with t(9;11)(p22;q23)-positive acute myeloid leukemia.
Scholl C; Schlenk RF; Eiwen K; Döhner H; Fröhling S; Döhner K;
Haematologica; 2005 Dec; 90(12):1626-34. PubMed ID: 16330435
[TBL] [Abstract][Full Text] [Related]
5. Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years.
Candoni A; Martinelli G; Toffoletti E; Chiarvesio A; Tiribelli M; Malagola M; Piccaluga PP; Michelutti A; Simeone E; Damiani D; Russo D; Fanin R
Leuk Res; 2008 Dec; 32(12):1800-8. PubMed ID: 18621416
[TBL] [Abstract][Full Text] [Related]
6. Nine years interval between first and second bone marrow transplantations and subsequent long-term survival--a case of acute myeloid leukemia with MLL-AF6 fusion gene.
Yokoyama Y; Suzukawa K; Okoshi Y; Nanmoku T; Obara N; Enami T; Hasegawa Y; Chiba S
Ann Hematol; 2012 Sep; 91(9):1491-3. PubMed ID: 22307741
[No Abstract] [Full Text] [Related]
7. Gemtuzumab ozogamicin: time to resurrect?
Ravandi F; Estey EH; Appelbaum FR; Lo-Coco F; Schiffer CA; Larson RA; Burnett AK; Kantarjian HM
J Clin Oncol; 2012 Nov; 30(32):3921-3. PubMed ID: 22987091
[No Abstract] [Full Text] [Related]
8. Sustained complete remission of recurrent acute myeloid leukaemia with a single dose of gemtuzumab ozogamicin and low-dose interleukin-2 maintenance.
Radsak MP; Salih HR; Sökler M; Kanz L; Denzlinger C
Leukemia; 2002 Sep; 16(9):1870-1. PubMed ID: 12200709
[No Abstract] [Full Text] [Related]
9. Gemtuzumab ozogamicin plus cytarabine determines complete remission in acute myeloid leukemia refractory to a double conventional treatment: a case report.
Mele A; Sparaventi G; Guiducci B; Nicolini G; d'Adamo F; Leopardi G; Delfini C; Piccaluga P; Visani G
Haematologica; 2004 Jun; 89(6 Suppl):ECR18. PubMed ID: 15194554
[No Abstract] [Full Text] [Related]
10. [Standard therapies for acute myeloid leukemia].
Matsumura I
Rinsho Ketsueki; 2009 Oct; 50(10):1389-400. PubMed ID: 19915347
[No Abstract] [Full Text] [Related]
11. Gemtuzumab ozogamicin: a component of induction therapy in AML?
Giles F
Leuk Res; 2005 Jan; 29(1):1-2. PubMed ID: 15541468
[No Abstract] [Full Text] [Related]
12. Efficacy and tolerability of gemtuzumab ozogamicin (anti-CD33 monoclonal antibody, CMA-676, Mylotarg) in children with relapsed/refractory myeloid leukemia.
Brethon B; Auvrignon A; Galambrun C; Yakouben K; Leblanc T; Bertrand Y; Leverger G; Baruchel A
BMC Cancer; 2006 Jun; 6():172. PubMed ID: 16805911
[TBL] [Abstract][Full Text] [Related]
13. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
Bross PF; Beitz J; Chen G; Chen XH; Duffy E; Kieffer L; Roy S; Sridhara R; Rahman A; Williams G; Pazdur R
Clin Cancer Res; 2001 Jun; 7(6):1490-6. PubMed ID: 11410481
[TBL] [Abstract][Full Text] [Related]
14. Comparative efficacy and safety of gemtuzumab ozogamicin monotherapy and high-dose cytarabine combination therapy in patients with acute myeloid leukemia in first relapse.
Leopold LH; Berger MS; Cheng SC; Cortes-Franco JE; Giles FJ; Estey EH
Clin Adv Hematol Oncol; 2003 Apr; 1(4):220-5. PubMed ID: 16224410
[TBL] [Abstract][Full Text] [Related]
15. Gemtuzumab ozogamicin with cytarabine and mitoxantrone as a third-line treatment in a poor prognosis group of adult acute myeloid leukemia patients: a single-center experience.
Specchia G; Pastore D; Carluccio P; Spinosa G; Giannoccaro M; Rizzi R; Mestice A; Liso V
Ann Hematol; 2007 Jun; 86(6):425-8. PubMed ID: 17364181
[TBL] [Abstract][Full Text] [Related]
16. Sequential targeted therapy for relapsed acute promyelocytic leukemia with all-trans retinoic acid and anti-CD33 monoclonal antibody M195.
Jurcic JG; Caron PC; Miller WH; Yao TJ; Maslak P; Finn RD; Larson SM; Warrell RP; Scheinberg DA
Leukemia; 1995 Feb; 9(2):244-8. PubMed ID: 7869759
[TBL] [Abstract][Full Text] [Related]
17. Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study.
Löwenberg B; Beck J; Graux C; van Putten W; Schouten HC; Verdonck LF; Ferrant A; Sonneveld P; Jongen-Lavrencic M; von Lilienfeld-Toal M; Biemond BJ; Vellenga E; Breems D; de Muijnck H; Schaafsma R; Verhoef G; Döhner H; Gratwohl A; Pabst T; Ossenkoppele GJ; Maertens J; ; ;
Blood; 2010 Apr; 115(13):2586-91. PubMed ID: 20103782
[TBL] [Abstract][Full Text] [Related]
18. The cytotoxic effects of gemtuzumab ozogamicin (mylotarg) in combination with conventional antileukemic agents by isobologram analysis in vitro.
Tanaka M; Kano Y; Akutsu M; Tsunoda S; Izumi T; Yazawa Y; Miyawaki S; Mano H; Furukawa Y
Anticancer Res; 2009 Nov; 29(11):4589-96. PubMed ID: 20032408
[TBL] [Abstract][Full Text] [Related]
19. Salvage therapy for acute myeloid leukemia with fludarabine, cytarabine, and idarubicin with or without gemtuzumab ozogamicin and with concurrent or sequential G-CSF.
Martin MG; Augustin KM; Uy GL; Welch JS; Hladnik L; Goyal S; Tiwari D; Monahan RS; Reichley RM; Cashen AF; Stockerl-Goldstein K; Westervelt P; Abboud CN; Dipersio JF; Vij R
Am J Hematol; 2009 Nov; 84(11):733-7. PubMed ID: 19806665
[TBL] [Abstract][Full Text] [Related]
20. Dismal long-term prognosis for children with refractory acute myeloid leukaemia treated with gemtuzumab ozogamicin and stem cell transplantation: where now?
Sibson K; Steward C; Moppett J; Cornish J; Goulden N
Br J Haematol; 2009 Aug; 146(3):342-4. PubMed ID: 19545292
[No Abstract] [Full Text] [Related]
[Next] [New Search]
